Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04701476 · ClinicalTrials.gov registry record · Phase 2
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
A Phase 2 study of Colorectal Cancer; Lung Cancer, sponsored by Teclison.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
- 3
- Study locations
NCT04701476 is a Phase 2 study of Colorectal Cancer; Lung Cancer that is actively recruiting participants, run by Teclison. The registered enrollment target is 110 participants. The trial reports 3 study locations across 2 states.
The verdict
NCT04701476, a Phase 2 study of Colorectal Cancer; Lung Cancer, is actively recruiting participants, sponsored by Teclison.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
- 3
- Study locations
Study Summary
Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
Conditions Studied
Interventions
- DRUG TATE and pembrolizumab
- DRUG TAS-102 pill
- DRUG Regorafenib Pill
Study Locations (3)
Other
- China Medical University Hsinchu Hospital - Hsinchu
- Chung Shan Medical University Hospital - Taichung
California
- University of California, Irvine Medical Center - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2021-05-20 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04701476
The ClinicalTrials.gov registry entry for NCT04701476 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teclison, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colorectal Cancer; Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which TATE and pembrolizumab is the first listed.
NCT04701476 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Other, California.
Frequently Asked Questions
What is clinical trial NCT04701476 about?
NCT04701476 is a clinical study titled "TATE and Pembrolizumab (MK3475) in mCRC and NSCLC". Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
What is the current status of trial NCT04701476?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2021-05-20. Estimated completion is 2025-12-31.
What conditions does trial NCT04701476 study?
This clinical trial studies the following conditions: Colorectal Cancer; Lung Cancer.
What interventions are being tested in trial NCT04701476?
The interventions under investigation include: TATE and pembrolizumab (DRUG), TAS-102 pill (DRUG), Regorafenib Pill (DRUG).
Who is sponsoring clinical trial NCT04701476?
This trial is sponsored by Teclison, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04701476 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.